Literature DB >> 28129096

Characterization of Anti- Dal Alloantibodies Following Sensitization of Two Dal-Negative Dogs.

S Goulet1, M C Blais1.   

Abstract

Since its discovery, the immunogenicity of the Dal blood type has not been further investigated. The aim of this study was to better characterize anti- Dal alloantibodies produced following sensitization of Dal-negative dogs, notably their rate of appearance, the agglutination titer over time, and their immunoglobulin class. A secondary objective was to obtain polyclonal anti- Dal alloantibodies to increase the availability of Dal blood typing. Of 100 healthy laboratory Beagles tested, 2 Dal-negative dogs were identified as recipients. Ten healthy Dal-positive dogs were investigated as potential blood donors. All dogs were extensively blood typed for DEA 1, 3, 4, 5, and 7, as well as for Dal. Then, the recipients were transfused uneventfully with 10 ml/kg of Dal-positive but otherwise compatible packed red blood cells. Posttransfusion blood samples were collected routinely over a minimum of 1 year. Using a gel column technology, anti- Dal alloantibodies were detected as early as 4 days posttransfusion and remained detectable 2 years posttransfusion, with maximum agglutination titers reached at 1 and 2 months posttransfusion. The immunoglobulin class was IgG. The immunogenicity and clinical significance of the Dal blood type were confirmed. The results support the recommendations that previously transfused dogs be crossmatched starting 4 days posttransfusion and for the animal's lifetime. The polyclonal anti- Dal antibodies produced will allow blood typing of a significant number of dogs, especially transfused dogs facing blood incompatibilities and canine blood donors.

Entities:  

Keywords:  agglutination; blood type; crossmatch; dog erythrocyte antigen; transfusion

Mesh:

Substances:

Year:  2017        PMID: 28129096     DOI: 10.1177/0300985816688746

Source DB:  PubMed          Journal:  Vet Pathol        ISSN: 0300-9858            Impact factor:   2.221


  7 in total

1.  Frequency of DEA 1 antigen in 1037 mongrel and PUREBREED dogs in ITALY.

Authors:  E Carli; A Carminato; S Ravagnan; K Capello; M T Antognoni; A Miglio; T Furlanello; D Proverbio; E Spada; A Stefani; F Mutinelli; M Vascellari
Journal:  BMC Vet Res       Date:  2017-11-29       Impact factor: 2.741

2.  Kai 1 and Kai 2: Characterization of these dog erythrocyte antigens by monoclonal antibodies.

Authors:  Jae Ho Lee; Urs Giger; Hee Young Kim
Journal:  PLoS One       Date:  2017-06-29       Impact factor: 3.240

3.  Prevalence and Mode of Inheritance of the Dal Blood Group in Dogs in North America.

Authors:  S Goulet; U Giger; J Arsenault; A Abrams-Ogg; C C Euler; M-C Blais
Journal:  J Vet Intern Med       Date:  2017-04-09       Impact factor: 3.333

Review 4.  Canine Blood Group Prevalence and Geographical Distribution around the World: An Updated Systematic Review.

Authors:  Sara Mangiaterra; Giacomo Rossi; Maria Teresa Antognoni; Matteo Cerquetella; Andrea Marchegiani; Arianna Miglio; Alessandra Gavazza
Journal:  Animals (Basel)       Date:  2021-01-29       Impact factor: 2.752

5.  Alloimmunization in dogs after transfusion: A serial cross-match study.

Authors:  Lisa Herter; Christiane Weingart; Nina Merten; Nicole Bock; Roswitha Merle; Barbara Kohn
Journal:  J Vet Intern Med       Date:  2022-08-19       Impact factor: 3.175

6.  Prevalence of Dal blood type and dog erythrocyte antigens (DEA) 1, 4, and 7 in canine blood donors in Italy and Spain.

Authors:  Daniela Proverbio; George Lubas; Eva Spada; Anyela Andrea Medina Valentin; Luis Miguel Viñals Florez; Maria Del Rosario Perlado Chamizo; Roberta Perego; Maria Grazia Pennisi; Elisabetta Ferro; Luciana Baggiani; Alessandra Gavazza; Marie-Claude Blais
Journal:  BMC Vet Res       Date:  2020-05-06       Impact factor: 2.741

7.  Identification of 5 novel feline erythrocyte antigens based on the presence of naturally occurring alloantibodies.

Authors:  Marie Binvel; Julie Arsenault; Boris Depré; Marie-Claude Blais
Journal:  J Vet Intern Med       Date:  2020-12-18       Impact factor: 3.175

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.